Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation TCT 2025

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

Presenter: Seung Hun Lee

October 26, 2025

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2022

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Presenter: Davide Capodanno

September 18, 2022

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT Abstracts Posters 2019

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Presenter: Young-Hyo Lim

October 21, 2019

Presentation TCT Abstracts Posters 2019

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Presenter: Young-Hyo Lim

September 29, 2019

Presentation TCT 2019

Case Resolution: How Did I Treat and What Happened?

Presenter: Amit Vora

September 26, 2019

Presentation TCT 2019

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Presenter: Bernard Chevalier

September 26, 2019

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

Presentation TCT 2019

Insights From SMART CHOICE

Presenter: Joo-Yong Hahn

September 26, 2019

Presentation TCT 2019

Insights From STOP DAPT-2

Presenter: Takeshi Kimura

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Insights From GLOBAL LEADERS and GLASSY

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

Presenter: Amit Vora

September 26, 2019

Presentation TCT 2018

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presenter: George D. Dangas, Germano Di Sciascio, Anne Tavenier

September 21, 2018

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Advertisement

TCT 52: Differential Prognostic Impact of Potent P2Y12 inhibitors in Patients with Acute Myocardial Infarction According to Bleeding Risk

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Case Resolution: How Did I Treat and What Happened?

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Insights From SMART CHOICE

Insights From STOP DAPT-2

Insights From TWILIGHT

Insights From GLOBAL LEADERS and GLASSY

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content